MSH|^~\\&|SISGDSP|SISGDSP|SISHIERECEIVER^9414049^L,M,N|^^L,M,N|20241018050017||ORU^R01^ORU_R01|005|P|2.5.1\r
PID|1||32550867^^^1013163542&NPI^MR||*****PII REMOVED******
NK1|1|*****PII REMOVED******
ORC|RE|753234567^FormNumber||56155532^HospOrdNumber||||||||^SCALA^MELISSA|||||||||STANFORD/LUCILE PACKARD CHILDREN'S HOSPI^^^^^^^^^R777|725 WELCH RD, RM  H1524^^PALO ALTO^CA^94304-1601\r
OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBR|1|753234567^FormNumber||54089-8^NB Screen Panel Patient AHIC|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBR|2|753234567^FormNumber||57128-1^Newborn Screening Report summary panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|CE|57721-3^Reason for lab test in Dried blood spot^LN|1|LA12421-6^Initial screen^LN|||N|||F|||20241018050017\r
OBX|2|CE|57718-9^Sample quality of Dried blood spot^LN|1|LA12432-3^Acceptable^LN|||N|||F|||20241018050017\r
OBX|3|CE|57130-7^Newborn screening report - overall interpretation^LN|1|LA18944-1^Screen is out of range for at least one condition^LN|||N|||F|||20241018050017\r
OBX|4|CE|57131-5^Newborn conditions with positive markers [Identifier] in Dried blood spot^LN|1|LA16207-5^Hemoglobinopathies^LN|||N|||F|||20241018050017\r
OBX|5|CE|57720-5^Newborn conditions with equivocal markers [Identifier] in Dried blood spot^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
OBX|6|TX|57724-7^Newborn screening short narrative summary^LN|1|ACTION REQUIRED\\.br\\\\.br\\NBS Testing Lab - ALLIED LABORATORY \\R\\453 RAVENDALE DR, STE B, MOUNTAIN VIEW, CA 94043-5221\\.br\\\\.br\\Genetic Disease Laboratory - GDL 850 MARINA BAY PKWY, # G265, RICHMOND, CA 94804-6403\\.br\\\\.br\\Lab Director - Genetic Disease Laboratory, (510) 231-1790\\.br\\\\.br\\Follow-up:\\.br\\\\.br\\Hb: An immediate referral to a CCS Hematology Center or a pediatric hematologist familiar with alpha thalassemia and Hb H disease is strongly recommended for this infant. \\.br\\\\.br\\If you have any questions regarding these screening outcomes, please contact the Newborn Screening Staff at Stanford University Medical Center at (650) 724-8120. \\.br\\\\.br\\Methods and Limitations:\\.br\\\\.br\\Assays for ALD Tier-1, BD, CAH, CF, GAL, MS/MS Acylcarnitine and Amino Acid Panels, PCH, hemoglobinopathies, and SCID were performed at the testing laboratory specified on the front of this report. Assays for ALD Tier-2, CAH Tier-2, GAMT, Pompe Disease Tier-1, MPS I Tier-1, MPS II Tier-1, and SMA were developed and/or optimized by the Genetic Disease Laboratory (GDL), and performed at GDL. Performance characteristics of these assays are determined by GDL. The SMA assay is designed to identify 95% of SMA patients who have homozygous deletions of the SMN1 gene on chromosome 5q. These assays have not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary. The assays are used for clinical purposes. They should not be regarded as investigational or for research. GDL is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88) to perform high complexity genetic disease screening. \\.br\\Attention Healthcare Provider:\\.br\\\\.br\\Due to biological variability and differences in detection rates for these disorders in the newborn period, genetic screening will not identify all positive cases. While a positive screening result identifies newborns at risk and justifies a diagnostic work-up, a negative screening result does not rule out the possibility of a disorder. Health care providers should remain watchful for any signs or symptoms of these disorders in their patients. Screening results are not diagnostic and cannot replace individualized evaluation and diagnosis of an infant from the healthcare provider. Newborn screening specimens collected at greater than 72 hours of age are outside the window of validation for analyte reference intervals and this may affect the accuracy of some screening results. \\.br\\\\.br\\|||N|||F|||20241018050017\r
OBX|7|TX|57129-9^Full newborn screening summary report for display or printing^LN|1||||N|||F|||20241018050017\r
OBR|3|753234567^FormNumber||57717-1^Newborn screen card data panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|ST|57716-3^State printed on filter paper card [Identifier] in NBS card^LN|1|CA|||N|||F|||20241018050017\r
OBX|2|NM|8339-4^Birthweight^LN|1|2658|grams||N|||F|||20241018050017\r
OBX|3|TM|57715-5^Time of birth^LN|1|0027|||N|||F|||20241018050017\r
OBX|4|CE|57722-1^Birth plurality of Pregnancy^LN|1|LA12411-7^Singleton^LN|||N|||F|||20241018050017\r
OBX|5|NM|73806-2^Newborn age in hours^LN|1|28|hour(s)||N|||F|||20241018050017\r
OBX|6|CE|57713-0^Infant NICU factors that affect newborn screening interpretation^LN|1|LA137-2^None^LN|||N|||F|||20241018050017\r
OBX|7|CE|67704-7^Feeding types^LN|1|LA16914-6^Breast milk^LN|||N|||F|||20241018050017\r
OBX|8|TX|^^^99717-5^Accession Number^L|1|272-95-009/21-2024-12|||N|||F|||20241018050017\r
OBX|9|TX|62324-9^Post-discharge provider name^LN|1|MELISSA SCALA|||N|||F|||20241018050017\r
OBX|10|TX|62327-2^Post-discharge provider practice address^LN|1|725 WELCH RD, RM H1524 PALO ALTO CA 94304-1601 USA|||N|||F|||20241018050017\r
OBR|4|753234567^FormNumber||57794-0^Newborn screening test results panel in Dried blood spot|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBR|5|753234567^FormNumber||53261-4^Amino acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|47633-3^Glycine [Moles/volume] in Dried blood spot^LN|1|926|µmol/L||N|||F|||20241018050017\r
OBX|2|NM|53150-9^Alanine+Beta Alanine+Sarcosine [Moles/volume] in Dried blood spot^LN|1|588|µmol/L|<1000|N|||F|||20241018050017\r
OBX|3|NM|47799-2^Valine [Moles/volume] in Dried blood spot^LN|1|79.4|µmol/L||N|||F|||20241018050017\r
OBX|4|NM|53151-7^Valine/Phenylalanine [Molar ratio] in Dried blood spot^LN|1|1.29739|{Ratio}|<4.3|N|||F|||20241018050017\r
OBX|5|NM|53152-5^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline^LN|1|99.2|µmol/L|<230|N|||F|||20241018050017\r
OBX|6|NM|53154-1^Alloisoleucine+Isoleucine+Leucine+Hydroxyproline/Alanine [Molar ratio] in Dried blood spot^LN|1|0.17|{Ratio}|<1.35|N|||F|||20241018050017\r
OBX|7|NM|29573-3^Phenylalanine [Moles/volume] in Dried blood spot^LN|1|61.2|µmol/L|<175|N|||F|||20241018050017\r
OBX|8|NM|35572-7^Phenylalanine/Tyrosine [Molar ratio] in Dried blood spot^LN|1|1.77|{Ratio}|<2.6|N|||F|||20241018050017\r
OBX|9|NM|35571-9^Tyrosine [Moles/volume] in Dried blood spot^LN|1|34.7|µmol/L|<680|N|||F|||20241018050017\r
OBX|10|NM|53231-7^Succinylacetone [Moles/volume] in Dried blood spot^LN|1|0.33|µmol/L|<6.1|N|||F|||20241018050017\r
OBX|11|NM|47700-0^Methionine [Moles/volume] in Dried blood spot^LN|1|20.4|µmol/L|6.3-100|N|||F|||20241018050017\r
OBX|12|NM|42892-0^Citrulline [Moles/volume] in Dried blood spot^LN|1|10|µmol/L|5-49|N|||F|||20241018050017\r
OBX|13|NM|54092-2^Citrulline/Arginine [Molar ratio] in Dried blood spot^LN|1|2.79|{Ratio}|<4.8|N|||F|||20241018050017\r
OBX|14|NM|53155-8^Asparagine+Ornithine [Moles/volume] in Dried blood spot^LN|1|43|µmol/L|<800|N|||F|||20241018050017\r
OBX|15|NM|75215-4^Ornithine/Citrulline [Molar ratio] in Dried blood spot^LN|1|4.44|{Ratio}||N|||F|||20241018050017\r
OBX|16|NM|47562-4^Arginine [Moles/volume] in Dried blood spot^LN|1|3|µmol/L|<63|N|||F|||20241018050017\r
OBX|17|NM|75214-7^Arginine/Ornithine [Molar ratio] in Dried blood spot^LN|1|0.08|{Ratio}|<1.9|N|||F|||20241018050017\r
OBX|18|NM|47732-3^Proline [Moles/volume] in Dried blood spot^LN|1|187|µmol/L|<1500|N|||F|||20241018050017\r
OBX|19|TX|57710-6^Amino acidemias newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|6|753234567^FormNumber||58092-8^Acylcarnitine newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|CE|58088-6^Acylcarnitine newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|2|TX|58093-6^Acylcarnitine newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|7|753234567^FormNumber||57084-6^Fatty acid oxidation newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|38481-8^Carnitine.free (C0)^LN|1|39.6|µmol/L|6.4-125|N|||F|||20241018050017\r
OBX|2|NM|53235-8^Carnitine.free (C0)/Palmitoylcarnitine (C16)+Stearoylcarnitine (C18)^LN|1|5.35|{Ratio}|<70|N|||F|||20241018050017\r
OBX|3|NM|50157-7^Acetylcarnitine (C2)^LN|1|34.7|µmol/L|10-80|N|||F|||20241018050017\r
OBX|4|NM|75212-1^Malonylcarnitine (C3-DC)/Decanoylcarnitine (C10) [Molar ratio] in Dried blood spot^LN|1|3.27536|{Ratio}|<7.6|N|||F|||20241018050017\r
OBX|5|NM|45211-0^Hexanoylcarnitine (C6)^LN|1|0.100|µmol/L|<0.95|N|||F|||20241018050017\r
OBX|6|NM|53175-6^Octanoylcarnitine (C8)^LN|1|0.075|µmol/L|<0.45|N|||F|||20241018050017\r
OBX|7|NM|53177-2^Octanoylcarnitine (C8)/Decanoylcarnitine (C10)^LN|1|1.09|{Ratio}||N|||F|||20241018050017\r
OBX|8|NM|53174-9^Octenoylcarnitine (C8:1)^LN|1|0.163|µmol/L|<0.65|N|||F|||20241018050017\r
OBX|9|NM|45197-1^Decanoylcarnitine (C10)^LN|1|0.069|µmol/L|<0.65|N|||F|||20241018050017\r
OBX|10|NM|45198-9^Decenoylcarnitine (C10:1)^LN|1|0.057|µmol/L|<0.45|N|||F|||20241018050017\r
OBX|11|NM|45199-7^Dodecanoylcarnitine (C12)^LN|1|0.118|µmol/L|<2|N|||F|||20241018050017\r
OBX|12|NM|45200-3^Dodecenoylcarnitine (C12:1)^LN|1|0.06|µmol/L||N|||F|||20241018050017\r
OBX|13|NM|53192-1^Tetradecanoylcarnitine (C14)^LN|1|0.394|µmol/L|<1.2|N|||F|||20241018050017\r
OBX|14|NM|53191-3^Tetradecenoylcarnitine (C14:1)^LN|1|0.130|µmol/L|<0.9|N|||F|||20241018050017\r
OBX|15|NM|53194-7^Tetradecenoylcarnitine (C14:1)/Dodecenoylcarnitine (C12:1)^LN|1|2.32|{Ratio}||N|||F|||20241018050017\r
OBX|16|NM|53190-5^Tetradecadienoylcarnitine (C14:2)^LN|1|0.03|µmol/L||N|||F|||20241018050017\r
OBX|17|NM|50281-5^3-Hydroxytetradecanoylcarnitine (C14-OH)^LN|1|0.026|µmol/L|<0.2|N|||F|||20241018050017\r
OBX|18|NM|53199-6^Palmitoylcarnitine (C16)^LN|1|5.52|µmol/L|<12|N|||F|||20241018050017\r
OBX|19|NM|53198-8^Palmitoleylcarnitine (C16:1)^LN|1|0.245|µmol/L|<1.4|N|||F|||20241018050017\r
OBX|20|NM|50125-4^3-Hydroxypalmitoylcarnitine (C16-OH)^LN|1|0.042|µmol/L|<0.1|N|||F|||20241018050017\r
OBX|21|NM|53201-0^3-Hydroxypalmitoylcarnitine (C16-OH)/Palmitoylcarnitine (C16)^LN|1|0.00761|{Ratio}|<0.07|N|||F|||20241018050017\r
OBX|22|NM|53241-6^Stearoylcarnitine (C18)^LN|1|2.13|µmol/L|<3.5|N|||F|||20241018050017\r
OBX|23|NM|53202-8^Oleoylcarnitine (C18:1)^LN|1|1.89|µmol/L|<7|N|||F|||20241018050017\r
OBX|24|NM|45217-7^Linoleoylcarnitine (C18:2)^LN|1|0.29|µmol/L||N|||F|||20241018050017\r
OBX|25|NM|50132-0^3-Hydroxystearoylcarnitine (C18-OH)^LN|1|0.032|µmol/L|<0.1|N|||F|||20241018050017\r
OBX|26|NM|50113-0^3-Hydroxyoleoylcarnitine (C18:1-OH)^LN|1|0.047|µmol/L|<0.1|N|||F|||20241018050017\r
OBR|8|753234567^FormNumber||57085-3^Organic acid newborn screen panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|53160-8^Propionylcarnitine (C3)^LN|1|4.2|µmol/L|<7.9|N|||F|||20241018050017\r
OBX|2|NM|53163-2^Propionylcarnitine (C3)/Acetylcarnitine (C2)^LN|1|0.12|{Ratio}|<0.42|N|||F|||20241018050017\r
OBX|3|NM|67708-8^Malonylcarnitine (C3-DC)+3-Hydroxybutyrylcarnitine (C4-OH)^LN|1|0.226|µmol/L|<0.48|N|||F|||20241018050017\r
OBX|4|NM|53166-5^Butyrylcarnitine+Isobutyrylcarnitine (C4)^LN|1|0.424|µmol/L|<1.7|N|||F|||20241018050017\r
OBX|5|NM|45216-9^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)^LN|1|0.247|µmol/L|<0.95|N|||F|||20241018050017\r
OBX|6|NM|53240-8^Isovalerylcarnitine+Methylbutyrylcarnitine (C5)/Propionylcarnitine (C3)^LN|1|0.05881|{Ratio}|<0.38|N|||F|||20241018050017\r
OBX|7|NM|53170-7^Tiglylcarnitine (C5:1)^LN|1|0.008|µmol/L|<0.5|N|||F|||20241018050017\r
OBX|8|NM|50106-4^3-Hydroxyisovalerylcarnitine (C5-OH)^LN|1|0.287|µmol/L|<1.15|N|||F|||20241018050017\r
OBX|9|NM|67710-4^Glutarylcarnitine (C5-DC)+3-Hydroxyhexanoylcarnitine (C6-OH)^LN|1|0.179|µmol/L|<0.38|N|||F|||20241018050017\r
OBX|10|NM|75216-2^Glutarylcarnitine (C5-DC)/Malonylcarnitine (C3-DC) [Molar ratio] in Dried blood spot^LN|1|0.79204|{Ratio}|>0.1|N|||F|||20241018050017\r
OBR|9|753234567^FormNumber||54078-1^Cystic fibrosis newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|48633-2^Trypsinogen I.free^LN|1|18.50|ng/mL|<69|N|||F|||20241018050017\r
OBX|2|CE|46769-6^Cystic fibrosis newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|57707-2^Cystic fibrosis newborn screening comment/discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|10|753234567^FormNumber||57086-1^Congenital adrenal hyperplasia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|38473-5^17-Hydroxyprogesterone^LN|1|00013.8|nmol/L|<85|N|||F|||20241018050017\r
OBX|2|CE|46758-9^Congenital adrenal hyperplasia newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|57706-4^Congenital adrenal hyperplasia newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|11|753234567^FormNumber||54090-6^Thyroid newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|29575-8^Thyrotropin^LN|1|2.40|mIU/L|<29|N|||F|||20241018050017\r
OBX|2|CE|46762-1^Congenital hypothyroidism newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|57705-6^Congenital hypothyroidism newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|12|753234567^FormNumber||54079-9^Galactosemia newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|42906-8^Galactose 1 phosphate uridyl transferase^LN|1|293.00|enzyme units|>50|N|||F|||20241018050017\r
OBX|2|CE|46737-3^Galactosemias newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|57704-9^Galactosemias newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|13|753234567^FormNumber||54081-5^Hemoglobinopathies newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|TX|54104-5^Hemoglobin pattern^LN|1|FA + Barts||||||F|||20241018050017\r
OBX|2|TX|57703-1^Hemoglobin disorders newborn screening comment/discussion^LN|1|The presence of Hb Barts at a high percentage is consistent with Hb H disease, a clinically significant hemoglobin disorder.||||||F|||20241018050017\r
OBR|14|753234567^FormNumber||57087-9^Biotinidase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|75217-0^Biotinidase [Enzymatic activity/volume] in Dried blood spot^LN|1|43.76|ERU|>10|N|||F|||20241018050017\r
OBX|2|CE|46761-3^Biotinidase deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|57699-1^Biotinidase deficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|15|753234567^FormNumber||62333-0^Severe combined immunodeficiency (SCID) newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|62320-7^T-cell receptor excision circle [#/volume] in Dried blood spot by Probe and target amplification method^LN|1|99|copies/µL|>18|N|||F|||20241018050017\r
OBX|2|CE|62321-5^Severe combined immunodeficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|62322-3^Severe combined immunodeficiency newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|16|753234567^FormNumber||63414-7^Pompe Disease newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|55827-0^Acid alpha glucosidase [Enzymatic activity/volume] in DBS^LN|1|7.09|µmol/L/h|>=1.67|N|||F|||20241018050017\r
OBX|2|CE|63415-4^Pompe Disease deficiency newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|63416-2^Pompe Disease deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|17|753234567^FormNumber||79563-3^Mucopolysaccharidosis type I newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|55909-6^Alpha-L-iduronidase [Enzymatic activity/volume] in DBS^LN|1|8.33|µmol/L/h|>=0.86|N|||F|||20241018050017\r
OBX|2|CE|79564-1^Mucopolysaccharidosis type I newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|79565-8^Mucopolysaccharidosis type I newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|18|753234567^FormNumber||92005-8^Spinal muscular atrophy newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|TX|^^^99717-60^SMN1 Homozygous Deletion Analysis^L|1|Exon 7 Present||Exon 7 Present|N|||F|||20241018050017\r
OBX|2|CE|92004-1^Spinal muscular atrophy newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|92003-3^Spinal muscular atrophy newborn screening comment-discussion^LN|1|SMA Negative|||N|||F|||20241018050017\r
OBR|19|753234567^FormNumber||104188-8^Mucopolysaccharidosis type II newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|79462-8^Iduronate-2-Sulfatase [Enzymatic activity/volume] in DBS^LN|1|15.65|µmol/L/h|>=2.8|N|||F|||20241018050017\r
OBX|2|CE|104189-6^Mucopolysaccharidosis type II newborn screen interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|3|TX|104190-4^Mucopolysaccharidosis type II newborn screening comment-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|20|753234567^FormNumber||104191-2^Guanidinoacetate methyltransferase newborn screening panel|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|CE|104192-0^Guanidinoacetate methyltransferase deficiency newborn screening interpretation^LN|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|2|TX|104193-8^Guanidinoacetate methyltransferase deficiency newborn screening comments-discussion^LN|1|Negative|||N|||F|||20241018050017\r
OBR|21|753234567^FormNumber||^^^99717-52^Guanidinoacetate methyltransferase Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|93488-5^Guanidinoacetate [moles/volume] in Dried blood spot^LN|1|1.05|µmol/L|<=3|N|||F|||20241018050017\r
OBX|2|NM|104194-6^Creatine [moles/volume] in Dried blood spot^LN|1|616.49|µmol/L||N|||F|||20241018050017\r
OBX|3|NM|104195-3^GUAC/CRE Ratio [moles/volume] in Dried blood spot^LN|1|1.70||<=6|N|||F|||20241018050017\r
OBR|22|753234567^FormNumber||^^^99717-28^Adrenoleukodystrophy newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|CE|^^^99717-32^Adrenoleukodystrophy deficiency newborn screening interpretation^L|1|LA18592-8^In range^LN|||N|||F|||20241018050017\r
OBX|2|TX|^^^99717-33^Adrenoleukodystrophy deficiency newborn screening comments-discussion^L|1|Negative|||N|||F|||20241018050017\r
OBR|23|753234567^FormNumber||^^^99717-29^Adrenoleukodystrophy Tier-1 newborn screening panel^L|||202409260512|||||||||^SCALA^MELISSA||||||20241018050017|||F\r
OBX|1|NM|79321-6^Lysophosphatidylcholine(26:0) [Moles/volume] in Dried blood spot^LN|1|0.260|µmol/L|<0.47|N|||F|||20241018050017\r
